(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 399.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,633.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,600.31%.
Soleno Therapeutics's revenue in 2026 is $98,675,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $26,477,431,024, with the lowest SLNO revenue forecast at $21,836,884,864, and the highest SLNO revenue forecast at $32,388,756,376.
In 2027, SLNO is forecast to generate $40,827,138,404 in revenue, with the lowest revenue forecast at $34,687,008,346 and the highest revenue forecast at $46,954,915,156.